C-7ZR4Akero Therapeutics
FGF21 analogue, metabolic disease, MASH
modulatingbiologic
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-7ZR4
C-7ZR4C-7ZR4FGF21 analogue, metabolic disease, MASH
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Akero Therapeutics states that NASH is a life-threatening global epidemic and that restoring metabolic balance is the key to halting or reversing its progression. The company presents its lead medicine, efruxifermin (formerly AKR-001), as a holistic treatment designed to mimic FGF21 biology, reduce liver fat, lower liver inflammation, inhibit collagen deposition, reverse fibrosis, and improve broader metabolic health, including lipoprotein profiles linked to cardiovascular risk.
SourceAkero Therapeutics states that serious metabolic diseases arise when the body’s carefully regulated metabolic balance is disrupted by environmental or genetic factors, and that restoring this balance through best-in-class medicines can meaningfully transform patients’ lives. The company presents metabolic homeostasis as a core biological principle, highlights the integration of glucose metabolism and fat synthesis across cells, organs, and the whole body, and frames its therapeutic approach as restoring that balance in diseases such as NASH.
SourceAkero Therapeutics states that human health depends on carefully calibrated metabolic balance across pathways such as glucose metabolism and fat synthesis, and that disruption of this balance by environmental or genetic factors can cause serious, potentially life-threatening disease. The company says it aims to develop best-in-class medicines that restore metabolic balance, particularly for NASH and other serious metabolic diseases, and believes its FGF21 agonist program could meaningfully improve patients' lives.
SourceAkero Therapeutics states that NASH is a life-threatening global disease and that restoring metabolic balance is the key therapeutic approach to halt its progression. The company presents AKR-001 as a holistic medicine intended to reduce liver fat, lower liver inflammation, inhibit collagen deposition, reverse fibrosis, and improve lipoprotein profiles, with the broader belief that addressing multiple underlying metabolic and pathological drivers of NASH can also reduce cardiovascular risk.
Source